

REFERENCES – TOWN HALL 79 –9-17-2022

COVID-19

BIVALENT BOOSTER DOSES FROM BOTH PFIZER AND MODERNA, THAT INCLUDE AN OMICRON-SPECIFIC COMPONENT, APPROVED FOR EMERGENCY USE AUTHORIZATION BY FDA AND ALSO APPROVED BY CDC'S ACIP.

<https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use>

<https://www.cdc.gov/media/releases/2022/s0901-covid-19-booster.html>

MOSAIC RECEPTOR-BINDING DOMAIN NANOPARTICLES PROTECT AGAINST CHALLENGE WITH DIVERSE SARBECOVIRUSES IN ANIMAL MODELS.

<https://www.science.org/doi/10.1126/science.abq0839>

EXCELLENT REVIEW – COVID-19 VACCINES — IMMUNITY, VARIANTS, BOOSTERS.

https://www.nejm.org/doi/full/10.1056/NEJMra2206573?query=featured_coronavirus

DURABILITY OF BOOSTER MRNA VACCINE AGAINST SARS-CoV-2 BA.2.12.1, BA.4, AND BA.5 SUBVARIANTS.

https://www.nejm.org/doi/full/10.1056/NEJMc2210546?query=featured_coronavirus

RELEVANCE OF ANTI-SPIKE MUCOSAL IGA PROTECTION AGAINST SARS-CoV-2 OMICRON INFECTION.

https://www.nejm.org/doi/full/10.1056/NEJMc2209651?query=featured_coronavirus

EVALUATION OF RISK FACTORS FOR POST-BOOSTER OMICRON COVID-19 DEATHS IN ENGLAND

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796000>

COVID-19-ASSOCIATED HOSPITALIZATIONS AMONG VACCINATED AND UNVACCINATED ADULTS 18 YEARS OR OLDER IN 13 US STATES, JANUARY 2021 TO APRIL 2022

<https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2796235>

HOW SHOULD AEROSOL GENERATING PROCEDURES BE DEFINED?

<https://www.bmj.com/content/378/bmj-2021-065903>

MONKEYPOX

MONKEYPOX VIRUS INFECTION IN HUMANS ACROSS 16 COUNTRIES — APRIL–JUNE 2022

<https://www.nejm.org/doi/full/10.1056/NEJMoa2207323>

MONKEYPOX – PAST AS PROLOGUE (EDITORIAL)

<https://www.nejm.org/doi/full/10.1056/NEJMe2210535>

TECOVIRIMAT AND THE TREATMENT OF MONKEYPOX — PAST, PRESENT, AND FUTURE CONSIDERATIONS

<https://www.nejm.org/doi/full/10.1056/NEJMp2210125>

NEW CDC GUIDANCE ABOUT THE USE OF TECOVIRIMAT.

<https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html>

INTRADERMAL VACCINATION FOR MONKEYPOX — BENEFITS FOR INDIVIDUAL AND PUBLIC HEALTH

<https://www.nejm.org/doi/full/10.1056/NEJMp2211311>

MONKEYPOX IN 2022—WHAT CLINICIANS NEED TO KNOW

<https://jamanetwork.com/journals/jama/fullarticle/2793516>

PREVENTION OF MONKEYPOX WITH VACCINES: A RAPID REVIEW

<https://www.thelancet.com/action/showPdf?pii=S1473-3099%2822%2900574-6>

HOW DOES MONKEYPOX SPREAD? WHAT SCIENTISTS KNOW

<https://www.nature.com/articles/d41586-022-02178-w>

MONKEYPOX SITUATION SUMMARY: CDC

<https://www.cdc.gov/poxvirus/monkeypox/response/2022/index.html>

MONKEYPOX DATA EXPLORER: OUR WORLD IN DATA

<https://ourworldindata.org/monkeypox>